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Abbreviations {#nc005}
=============

HF

:   heart failure

PLR

:   platelet/lymphocyte ratio

NSTEMI

:   non-ST-elevation myocardial infarction

STEMI

:   ST elevation myocardial infarction

MI

:   myocardial infarction

PCI

:   percutaneous coronary intervention

SCAD

:   stable coronary artery disease

CABG

:   coronary artery bypass grafting

COPD

:   chronic obstructive pulmonary disease

BMI

:   body mass index

EF

:   ejection fraction

Hb

:   hemoglobin

eGFR

:   estimated glomerular filtration rate

CKD-EPI

:   Chronic Kidney Disease Epidemiology Collaboration

CCS

:   Canadian Cardiovascular Society

NYHA

:   New York Heart Association

Introduction {#s0005}
============

Numerous studies have shown the association between elevated platelet counts and cardiovascular mortality [@b0005; @b0010; @b0015]. It has been also shown that the elevated level of neutrophils and relative lymphocytopenia are negative prognostic indexes of outcomes in patients with coronary artery disease and heart failure (HF) [@b0020; @b0025; @b0030; @b0035; @b0040; @b0045].

Platelet-to-lymphocyte ratio (PLR) which can be derived from the complete blood count is a novel index reflecting a systemic inflammatory burden that combines prognostic values of an individual's platelet and lymphocyte count [@b0020; @b0045]. In patients with non-ST-elevation myocardial infarction (NSTEMI) and ST elevation myocardial infarction (STEMI), the PLR ratio is an independent predictor of mortality [@b0050; @b0055].

Moreover, in patients with myocardial infarction (MI) treated by primary PCI, PLR is an independent risk factor for more advanced coronary artery disease as reflected by higher Syntax scores and no-reflow phenomenon [@b0060]. Data regarding PLR and its association with long-term prognosis in stable coronary artery disease (SCAD) patients are, however, lacking. We hypothesized that PLR is a potential marker of prognostic importance in patients with SCAD. The aim of our study was to establish the impact of the baseline PLR ratio on all-cause, long-term mortality in patients after PCI and stent implantation.

Methods {#s0010}
=======

Data collection {#s0015}
---------------

For the purpose of this study, we examined a computer database to identify patients with SCAD referred to the Silesian Center for Heart Diseases in Poland who underwent coronary angiography and stent implantation between July 2006 and December 2011. In this database, information on coronary intervention, concomitant diseases, demographic data and laboratory parameters such as platelet and leukocyte counts are stored. The complete blood counts, which included total white blood cells, neutrophils, lymphocytes and platelets, were obtained using an automated blood counter Sysmex XS1000i and XE2100 (Sysmex Corporation, Kobe, Japan). Platelet-to-lymphocyte ratio was calculated as the ratio of the platelets to lymphocytes, obtained from the blood samples that were taken at the fasting state.

Patients undergoing hybrid revascularization, patients after orthotropic heart transplant, patients with known hematological diseases, patients on dialysis, or with other diseases limiting survival were excluded from the analysis. One patient died during the in-hospital period due to periprocedural complications. This patient was also excluded from this analysis.

The study was approved by the Local Ethics Committee at the District Chamber of Physicians.

Follow-up data {#s0020}
--------------

Information on survival was based on the National Health Fund insurance status, which can be electronically verified because the National Health Fund insurance policy is obligatory for all Polish citizens, and patients who were insured were marked as alive. We made an attempt to contact the relatives of uninsured patients and/or the relevant local registry office to obtain the date of death. Complete follow-up data (including eventual event and time of the event) were available for 2947 (99.6%) patients.

Statistical analysis {#s0025}
--------------------

The normality of continuous variable distribution was tested with a Shapiro-Wilk test and deviation from the normal distribution was inspected by analysis of the normal probability plots (Quantile-Quantile plots). The continuous variables are not normally distributed, and are therefore presented as median and interquartile ranges. The dichotomous variables are presented as percentages. Patients were divided into sub-groups according to PLR tertiles. Group I included patients with PLR \< 87 (*n* = 986); group II included patients with PLR value of ⩾87 and \< 121 (*n* = 986); and group III included patients with PLR ⩾ 121 (*n* = 987).

To test for differences between the groups, the Kruskal--Wallis test and chi-square test were used for continuous variables, and dichotomous variables, respectively. The associations between groups and mortality were analyzed using the Kaplan-Meier method with log-rank testing. To assess the impact of the PLR on prognosis, a univariable and multivariable Cox regression analysis was performed. Variables used in the univariable Cox regression analysis included clinical, angiographic, and laboratory parameters. Sex, history of MI, previous PCI, previous coronary artery bypass grafting (CABG), previous stroke, hypercholesterolemia, hypertension, atrial fibrillation, diabetes, chronic obstructive pulmonary disease (COPD), family history of premature (\<55 years of age) MI and sinus rhythm at admission were analyzed as dichotomous variables. Age, body mass index (BMI), ejection fraction (EF), hemoglobin (Hb), creatinine, sodium, and total cholesterol were analyzed as a continuous variable. Estimated glomerular filtration rate (eGFR) was calculated by the Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) formula [@b0065] and was analyzed as a continuous variable, per 10 ml/min/1.73m2 increment. PLR was analyzed as a continuous variable per 10 units increase. Admission platelets and lymphocyte counts were excluded from the analysis as they were used to calculate PLR. The Canadian Cardiovascular Society (CCS) class was categorized as CCS class I and II vs. CCS class III and IV. Heart failure was categorized as "no heart failure" and "heart failure with symptoms in New York Heart Association Class (NYHA) I/II" and "heart failure with symptoms in NYHA class III/IV". Smoking was categorized as "current smoker", "former smoker" and "never smoked". Type of stent implanted was categorized as "bare metal stent", "drug eluting stent" or "both". The number of stents implanted and number of PCI vessels were analyzed as ordinal categories. To minimize the impact of missing data on the Cox regression analysis, the multiple imputation method was used to impute missing data for the variables that were to be included in the Cox regression procedures. There were missing data regarding information on the BMI -- 253 (8.6%), EF -- 314 (10.6%), family history of premature coronary heart disease -- 8 (0.3%). Hemodynamic data was available for all patients and was taken from angiography reports. Data on mortality was missing for 14 (0.5%) patients. Additionally for three (0.1%) patients, we were not able to establish the exact time of death.

To minimize the impact of the missing data on the multivariable Cox regression analysis, we used the missForest algorithm for mixed type data imputation [@b0070]. All above-mentioned variables including the outcome variable were entered into the multiple imputation algorithm. We used the missForest R--package [@b0075].

We performed Cox regression analysis on the imputed dataset. Variables that reached *p*-value lower than 0.2 in the univariable analysis were included in the multivariable model. We used backwards selection procedures to obtain variables significantly associated with long-term mortality in multivariable analysis. We created four models including PLR and clinical variables (model 1), clinical variables and ejection fractions (model 2), clinical variables, ejection fractions and angiographic parameters (number of stents implanted, number of PCI vessels, presence of multi-vessel coronary artery disease) (model 3), and additionally also hemoglobin and eGFR (model 4). We calculated Harrell's concordance index (Harrell's C-statistics) which describes discriminative ability of risk models obtained with the use of Cox-regression analysis. Harrell's C-statistics range from 0.5 (no predictive ability) to 1.0 (perfect discrimination). The analyses were performed using Number Crunching Statistical Systems 8.0 (NCSS, Kaysville, UT, USA) and R software [@b0080] Figure was prepared using Graph Pad Prism Software (La Jolla, USA).

The creation of the database of patients with SCAD used in this study was supported by the National Science Center -- Dec-2011/01/D/NZ5/04387.

Results {#s0030}
=======

The study sample consisted of a cohort of 2959 patients with SCAD (2094 males), with a median age of 64.00 (IQR: 57 ÷ 71 years). The baseline demographic characteristics of patients stratified by the PLR tertiles are demonstrated in [Table 1](#t0005){ref-type="table"}. The patients in the 3rd PLR tertile were significantly older, more often female and hypertensive whilst less often smokers and obese, as compared to patients in the 1st and 2nd PLR tertile. According to the admission laboratory work-up, patients in the 3rd PLR tertile had significantly lower red and white blood cell counts, sodium concentration, Hb levels and eGFR ([Table 2](#t0010){ref-type="table"}). There were no differences between patients stratified by the PLR tertiles in the prescribed treatment at hospital discharge ([Table 3](#t0015){ref-type="table"}).

PLR and Outcomes {#s0035}
----------------

Follow-up data (including eventual event and time of the event) were available for 2947 (99.6%) patients. The median follow-up was 1124 days (interquartile range 586 ÷ 1594 days). During the observation period, 287 deaths were reported. Mortality was highest in the 3rd tertile 108/983 (11.0%) as compared to the 1st 94/981 (9.6%) and 2nd tertile 85/981 (8.7%) (*p *= 0.03, log rank). Kaplan--Maier curves for survival are depicted in [Fig. 1](#f0005){ref-type="fig"}.

Platelet-to-lymphocyte ratio was significantly associated with mortality in the univariable analysis ([Fig. 2](#f0010){ref-type="fig"}). It remained significantly associated with long-term mortality after consecutive adjustments for clinical variables (model 1), EF (model 2) and angiographic data (model 3). However, after adjustment for hemoglobin and eGFR, PLR was no longer significantly associated with the outcomes (model 4, [Fig. 2](#f0010){ref-type="fig"}).

Discussion {#s0040}
==========

Platelet-to-lymphocyte ratio is a repeatable and easily obtainable blood index of the systemic inflammatory burden that combines both a prognostic value of the individual platelet and lymphocyte counts [@b0020; @b0045]. It has been found to be elevated in patients suffering from various oncologic disorders [@b0085]. Platelet-to-lymphocyte ratio is a predictor of mortality in a cancer population [@b0090; @b0095; @b0100; @b0105] and a useful biomarker for predicting response to first-line chemotherapy [@b0110].

Some studies have identified high platelet counts and worse outcomes after PCI [@b0010; @b0015], and the negative predictive role of lymphocyte counts in patients with coronary artery disease [@b0035], unstable angina [@b0030], and heart failure [@b0020; @b0025; @b0040; @b0045; @b0115]. To our knowledge, no research has evaluated the significance of the PLR value in predicting long-term mortality in SCAD patients treated by elective PCI.

Gary et al. [@b0120] reported that in patients with peripheral arterial occlusive disease, PLR ratio value of more than 150 can be used to discriminate patients at high risk for critical limb ischemia from those with a low risk. Additionally, it has been demonstrated that elevated platelet counts were independently associated with platelet resistance to aspirin [@b0125], and increased PLR with a risk of thrombosis of prosthetic valves [@b0130]. In our study, patients within the 3rd PLR tertile value were older, with a higher prevalence of female gender, a lower frequency of smoking, and lower body mass index compared to those within lower PLR tertiles. In addition, patients in the 3rd PLR tertile were more frequently hypertensive and had a higher heart rate at admission. The results of our study are in line with the findings of Gary at al, suggesting age influences on the PLR value [@b0120].

Platelet-to-lymphocyte ratio was also found to be a marker of long-term mortality in patients with MI [@b0050; @b0060], and it was associated with more advanced coronary artery disease, in-hospital adverse events, and stent thrombosis in patients with STEMI treated with primary PCI [@b0135; @b0140].

In our study, we are able to demonstrate that a high PLR is a predictor of poor outcomes in patients after PCI and stent implantation after adjusting for clinical features, EF, and angiographic parameters ([Fig. 2](#f0010){ref-type="fig"}), but not after adjustment for hemoglobin and eGFR, which are well known predictors of long-term prognosis in that group of patients [@b0145; @b0150].

The mechanisms of the poor long-term outcomes of patients with elevated PLR discussed in the literature are multifactorial and not fully understood. It has long been recognized that low grade inflammation plays a key role in all aspects of atherosclerosis, including plaque formation, plaque rupture, and thrombosis. Prior studies reveal an association between major adverse cardiovascular outcomes and both higher platelet and low lymphocyte counts in patients with NSTEMI [@b0050].

Abnormally low lymphocyte count was found to be a predictor of an overall mortality and MI in patients presenting to the emergency room with chest pain [@b0155], and was associated with adverse clinical outcomes in patients with SCAD and NSTEMI [@b0035; @b0050]. On the contrary as platelets release over 300 proteins and molecules, including chemokines, and coagulation factors [@b0160], higher platelet counts may reflect underlying inflammation and thrombocyte activation. In connection with its ability to 'cross-talk' with endothelial cells and leukocytes, platelets release substances that increase adhesion and transmigration of monocytes, therefore leading to a more aggressive course of atherosclerosis [@b0165; @b0170]. Indeed, platelet-neutrophil binding occurs after PCI [@b0175]. However, inflammatory mediators and stress-induced steroid exposure can decrease the number of lymphocytes and hence modify the PLR [@b0180]. At the end-stage renal disease, PLR is also positively correlated with the neutrophil-to-lymphocyte ratio, interleukin-6 and tumor necrosis factor-α, which are known mediators of inflammation [@b0185]. Apart from its pro-inflammatory rating, PLR is also positively correlated with fibrinogen which leads to an increase in blood viscosity and therefore impairment of the tissue oxygen supply [@b0120; @b0190; @b0195]. This is in line with both the study by Ayça et al, which proves that PLR is a predictor of no-reflow phenomenon in STEMI patients, and with our previous publication showing that baseline fibrinogen concentration in STEMI patients is an independent risk factor of the lack of myocardial reperfusion [@b0135; @b0200].

It has been also reported that an elevated platelet count is an independent predictor of aspirin resistance which may also affect outcomes in patients treated with stent implantation [@b0125].

In summary, PLR is a surrogate marker of systemic inflammation and, as such, may provide an explanation for increased cardiovascular risk. Moreover, it could be assumed that high platelet concentrations and low lymphocyte counts may contribute to the progression of atherosclerosis, may accelerate restenosis and plaque instability, and hence be associated with worse prognosis in SCAD and patients with MI [@b0050; @b0055].

Strengths and limitations {#s0045}
-------------------------

This study has several limitations. It is a single-center retrospective study, and we used a single blood sample to calculate PLR. Nonetheless, the potential disadvantages of the retrospective analysis are diminished by the fact that patients' data were inputted into an electronic database from report forms filled out by the attending physician upon the patient's admission to our center. Strengths of this study include large cohort, detailed data on clinical, hemodynamic and laboratory parameters, and a long follow-up period with very few patients lost to follow-up.

Conclusion {#s0050}
==========

Mortality in patients with SCAD undergoing elective stent implantation is higher in patients with the highest PLR values; and PLR has predictive value for all-cause long-term mortality in patients undergoing PCI and stent implantation, even after adjusting for the possible confounders, including clinical features, EF and angiographic data but not laboratory parameters. Future studies are warranted to clarify the prognostic value of PLR on cardiovascular event rates and all-cause mortality in SCAD patients.

The creation of the database of patients with SCAD used in this study was supported by the National Science Center -- Dec-2011/01/D/NZ5/04387.

![Kaplan--Meier survival plots for risk of death from all-cause, categorized according to the PLR ratio tertiles during follow-up.](gr1){#f0005}

![Risk associated with an increase in PLR in the setting of unadjusted analysis and after inclusion of clinical variables (model 1, Harrell's C-statistics 0.742 \[0.71 ÷ 0.77\]), ejection fraction (model 2, Harrell's C-statistics 0.745 \[0.71 ÷ 0.78\]), angiographic data (model 3, Harrell's C-statistics 0.749 \[0.72 ÷ 0.78\]) and laboratory parameters (model 4, Harrell's C-statistics -- 0.762 \[0.73 ÷ 0.79\]).](gr2){#f0010}

###### 

Baseline clinical characteristics of analyzed cohort according to PLR values.

  Variable                       1st tertile, (*n* = 986)   2nd tertile, (*n* = 986)   3rd tertile, (*n* = 987)   *P* value            
  ------------------------------ -------------------------- -------------------------- -------------------------- -------------------- --------
  Age (yrs)                      62.0 \[56.0 ÷ 69.0\]       65.0 \[57.0 ÷ 71.0\]       65.0 \[58.0 ÷ 72.0\]       \<0.01               
  Men (%)                                                   746 (75.7%)                693 (70.3%)                655 (66.4%)          \<0.01
  Heart failure                  NYHA class I/II            107 (10.9%)                93 (9.4%)                  101 (10.2%)          0.70
  NYHA class III/IV              33 (3.3%)                  42 (4.3%)                  40 (4.1%)                                       
  Atrial fibrillation            104 (10.5%)                106 (10.8%)                110 (11.1%)                0.91                 
  Hypertension                   698 (70.8%)                686 (69.6%)                740 (75.0%)                0.02                 
  Previous MI                    578 (58.6%)                562 (57.0%)                589 (59.7%)                0.48                 
  Previous CABG                  136 (13.8%)                134 (13.6%)                108 (10.9%)                0.11                 
  Previous PCI                   460 (46.9%)                485 (49.4%)                504 (51.1%)                0.17                 
  Previous SCD                   28 (2.8%)                  31 (3.1%)                  26 (2.6%)                  0.79                 
  PVD                            66 (6.7%)                  48 (4.9%)                  54 (5.5%)                  0.20                 
  Prev. Stroke/TIA               39 (4.0%)                  47 (4.8%)                  46 (4.7%)                  0.64                 
  Diabetes mellitus              366 (37.1%)                344 (34.9%)                365 (37.0%)                0.51                 
  Lipid abnormalities            576 (58.4%)                564 (57.2%)                544 (55.1%)                0.33                 
  COPD                           68 (6.9%)                  71(7.2%)                   76 (7.7%)                  0.79                 
  Obesity                        328 (36.5%)                300 (33.3%)                264 29.1 (%)               \<0.01               
  Current smoker                 144 (14.6%)                97 (9.9%)                  89 (9.0%)                  \<0.01               
  Previous smoker                376 (38.2%)                356 (36.2%)                343 (34.8%)                                     
  FH of premature                87 (8.8%)                  96 (9.8%)                  87 (8.8%)                  0.71                 
  CCS class                      I/II                       826 (83.8%)                821 (83.3%)                832 (84.3%)          0.82
  III/IV                         160 (16.2%)                165 (16.7%)                155 (15.7%)                                     
  In sinus rhythm at admission   64 (6.5%)                  54 (5.5%)                  59 (6.0%)                  0.63                 
  Ejection fraction (%)          48.0 \[40.0 ÷ 53.5\]       48.0 \[40.0 ÷ 55.0\]       50.0 \[42.0 ÷ 55.0\]       0.08                 
  BMS                            582 (59.0%)                529 (53.7%)                535 (54.2%)                0.11                 
  DES                            368 (37.3%)                417 (42.3%)                417 (42.2%)                                     
  BMS + DES                      36 (3.7%)                  40 (4.1%)                  35 (3.5%)                                       
  MVD                            194 (19.7%)                189 (19.2%)                196 (19.9%)                0.92                 
  No. of PCI vessels             1                          786 (79.7%)                781 (79.2%)                791 (80.1%)          0.60
  No. of PCI vessels             2                          166 (16.8%)                176 (17.8%)                168 (17.0%)          
  No. of PCI                     3                          34 (3.0%)                  29 (2.7%)                  28 (2.3%)            
  No. of stents                  1                          715 (72.5%)                678 (68.8%)                679 (68.8%)          0.62
  No. of stents                  2                          212 (21.5%)                246 (24.9%)                241 (24.4%)          
  No. of stents                  3                          48 (4.9%)                  54 (5.5%)                  58 (5.9%)            
                                 ⩾4                         10 (0.7%)                  8 (0.7%)                   9 (0.7%)             
  BMI                                                       28.4 \[26.0÷31.3\]         28.0 \[25.3÷30.8\]         27.7 \[25.2÷30.5\]   \<0.01

*Abbreviations:* BMI - body mass index, BMS -- bare metal stent, CABG -- coronary artery bypass grafting, CCS -- Canadian Cardiovascular Society, COPD - chronic obstructive pulmonary disease, DES -- drug-eluting stent, FH -- family history, MI -- myocardial infarction, MVD -- multivessel disease, NYHA -- New York Heart Association, PCI -- percutaneous coronary intervention, PVD -- peripheral vascular disease, SCD - sudden cardiac death, TIA - transient ischemic attack.

###### 

Laboratory findings at hospital admission in the analyzed cohort according to PLR values.

  Variable                    1st tertile, *N* = 986    2nd tertile, *N* = 986    3rd tertile, *N* = 987    P value
  --------------------------- ------------------------- ------------------------- ------------------------- ---------
  RBC (10^6^/mm^3^)           4.6 \[4.3 ÷ 4.9\]         4.5 \[4.2 ÷ 4.8\]         4.5 \[4.1 ÷ 4.8\]         \<0.01
  Hb (mmol/l)                 8.8 \[8.2 ÷ 9.3\]         8.7 \[8.1 ÷ 9.2\]         8.4 \[7.8 ÷ 9.0\]         \<0.01
  HCT (%)                     42.0 \[39.0 ÷ 45.0\]      41.0 \[39.0 ÷ 44.0\]      37.0 \[40.0 ÷ 44.0\]      \<0.01
  WBC (10^3^/mm^3^)           7.6 \[6.4 ÷ 8.9\]         6.8 \[5.9 ÷ 8.1\]         6.8 \[5.7 ÷ 8.1\]         \<0.01
  Neutrophils (10^3^/mm^3^)   4.0 \[3.2 ÷ 5.0\]         4.0 \[3.2 ÷ 5.0\]         4.3 \[3.5 ÷ 5.5\]         \<0.01
  Lymphocyte (10^3^/mm^3^)    2.6 \[2.2 ÷ 3.1\]         2.0 \[1.7 ÷ 2.3\]         1.5 \[1.2 ÷ 1.8\]         \<0.01
  PLT (10^3^/mm^3^)           176 \[148 ÷ 206\]         204 \[175 ÷ 236\]         239 \[203 ÷ 283\]         \<0.01
  eGFR (ml/min/1.73 m^2^)     85.5\[71.0 ÷ 96.1\]       85.4 \[69.4 ÷ 95.3\]      84.1 \[67.6 ÷ 94.9\]      \<0.01
  Sodium (mmol/l)             138.9 \[137.1 ÷ 140.4\]   138.6 \[137.0 ÷ 140.2\]   138.2 \[136.6 ÷ 139.9\]   \<0.01
  Cholesterol (mmol/l)        4.4 \[3.7 ÷ 5.2\]         4.4 \[3.7 ÷ 5.2\]         4.4 \[3.6 ÷ 5.2\]         0.71
  PLR                         70.0 \[59.7 ÷ 78.1\]      102.3 \[94.3 ÷ 111.7\]    149.4 \[132.5 ÷ 183.2\]   \<0.01

*Abbreviations:* eGFR -- estimated glomerular filtration rate, Hb -- hemoglobin, HCT -- hematocrit, PLR -- platelet/lymphocyte ratio, PLT -- platelets, RBC -- red blood cells, WBC -- white blood cells.

###### 

Treatment at hospital discharge according to PLR values.

  Variable          1st tertile, *N* = 986   2nd tertile, *N* = 986   3rd tertile, *N* = 987   *P* value
  ----------------- ------------------------ ------------------------ ------------------------ -----------
  Aspirin           975 (98.9%)              977 (99.1%)              975 (98.8%)              0.80
  Thienopyridines   975 (98.9%)              978 (99.2%)              984 (99.7%)              0.11
  ACE-I/ARB         928 (94.1%)              920 (93.3%)              923 (93.5%)              0.65
  Beta-blockers     946 (95.9%)              942 (95.5%)              945 (95.7%)              0.91
  Diuretics         349 (35.4%)              335 (34.0%)              368 (37.3%)              0.31
  Statin            955 (96.9%)              953 (96.7%)              948 (96.0%)              0.59

*Abbreviations:* ACE-I -- angiotensin converting enzyme inhibitors, ARB -- angiotensin receptor blockers.
